SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 75 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $133,000 | +17.7% | 25,344 | 0.0% | 0.00% | – |
| Q4 2018 | $113,000 | -72.4% | 25,344 | -50.0% | 0.00% | – |
| Q3 2018 | $410,000 | +129.1% | 50,688 | +98.2% | 0.00% | – |
| Q2 2018 | $179,000 | -50.8% | 25,568 | 0.0% | 0.00% | – |
| Q1 2018 | $364,000 | +130.4% | 25,568 | +41.9% | 0.00% | – |
| Q4 2017 | $158,000 | -12.7% | 18,016 | +16.6% | 0.00% | – |
| Q3 2017 | $181,000 | -16.2% | 15,451 | 0.0% | 0.00% | – |
| Q2 2017 | $216,000 | +113.9% | 15,451 | +109.9% | 0.00% | – |
| Q1 2017 | $101,000 | +90.6% | 7,360 | 0.0% | 0.00% | – |
| Q4 2016 | $53,000 | -28.4% | 7,360 | +49.9% | 0.00% | – |
| Q3 2016 | $74,000 | +54.2% | 4,911 | 0.0% | 0.00% | – |
| Q2 2016 | $48,000 | – | 4,911 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |